Genedx Holdings (WGS) | Financial Analysis & Statements
Genedx Holdings Corp Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
121.0M
Gross Profit
84.3M
69.65%
Operating Income
-14.2M
-11.77%
Net Income
-17.7M
-14.60%
Balance Sheet Metrics
Total Assets
523.7M
Total Liabilities
215.5M
Shareholders Equity
308.2M
Debt to Equity
0.70
Cash Flow Metrics
Operating Cash Flow
-7.2M
Free Cash Flow
-7.4M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Genedx Holdings Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 427.5M | 305.4M | 202.6M | 234.7M | 212.2M |
| Cost of Goods Sold | 129.4M | 111.1M | 112.6M | 261.4M | 228.8M |
| Gross Profit | 298.2M | 194.4M | 90.0M | -26.8M | -16.6M |
| Gross Margin % | 69.7% | 63.6% | 44.4% | -11.4% | -7.8% |
| Operating Expenses | |||||
| Research & Development | 72.0M | 45.7M | 58.3M | 86.2M | 105.2M |
| Selling, General & Administrative | 239.2M | 168.5M | 194.7M | 338.2M | 318.7M |
| Other Operating Expenses | - | 3.4M | 7.2M | 6.3M | 5.7M |
| Total Operating Expenses | 311.2M | 217.6M | 260.2M | 430.8M | 429.5M |
| Operating Income | -13.1M | -23.2M | -170.2M | -457.5M | -446.1M |
| Operating Margin % | -3.1% | -7.6% | -84.0% | -194.9% | -210.3% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | 2.5M | 79.0K |
| Interest Expense | - | - | - | 3.2M | 2.8M |
| Other Non-Operating Income | -5.5M | -26.4M | -7.6M | -139.9M | 203.5M |
| Pre-tax Income | -21.1M | -52.6M | -176.7M | -598.0M | -245.4M |
| Income Tax | -116.0K | -343.0K | -926.0K | -49.1M | 0 |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -21.0M | -52.3M | -175.8M | -549.0M | -245.4M |
| Net Margin % | -4.9% | -17.1% | -86.8% | -233.9% | -115.6% |
| Key Metrics | |||||
| EBITDA | 13.4M | 12.1M | -127.2M | -258.3M | -419.1M |
| EPS (Basic) | - | $-1.94 | $-7.23 | $-53.79 | $-74.91 |
| EPS (Diluted) | - | $-1.94 | $-7.23 | $-53.79 | $-74.91 |
| Basic Shares Outstanding | - | 26891213 | 24311989 | 10236959 | 3275073 |
| Diluted Shares Outstanding | - | 26891213 | 24311989 | 10236959 | 3275073 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Genedx Holdings Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 105.0M | 85.2M | 99.7M | 123.9M | 400.6M |
| Short-term Investments | 66.3M | 56.0M | 30.5M | 0 | - |
| Accounts Receivable | 74.4M | 37.4M | 32.4M | 42.6M | 26.5M |
| Inventory | 14.0M | 10.6M | 8.8M | 13.7M | 33.5M |
| Other Current Assets | 1.5M | 1.1M | 2.0M | 31.7M | 23.0M |
| Total Current Assets | 268.3M | 198.0M | 182.3M | 212.6M | 483.5M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 56.3M | 47.2M | 45.0M | 95.4M | 49.9M |
| Goodwill | 195.5M | 158.6M | 172.6M | 186.6M | 0 |
| Intangible Assets | 168.5M | 158.6M | 172.6M | 186.6M | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 4.3M | 4.3M | 4.4M | 7.4M | 7.8M |
| Total Non-Current Assets | 255.4M | 221.4M | 236.4M | 278.3M | 70.5M |
| Total Assets | 523.7M | 419.4M | 418.8M | 490.9M | 554.1M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 2.5M | 8.0M | 10.2M | 46.0M | 44.7M |
| Short-term Debt | 8.9M | 3.3M | 3.6M | 10.9M | 3.4M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 11.3M | 2.8M | 2.0M | 24.7M | 8.9M |
| Total Current Liabilities | 108.9M | 54.8M | 58.8M | 144.3M | 101.3M |
| Non-Current Liabilities | |||||
| Long-term Debt | 104.2M | 112.8M | 115.6M | 66.3M | 11.0M |
| Deferred Tax Liabilities | 757.0K | 965.0K | 1.6M | 2.7M | 0 |
| Other Non-Current Liabilities | 1.6M | - | - | 1.6M | 32.2M |
| Total Non-Current Liabilities | 106.6M | 119.3M | 131.9M | 92.9M | 64.7M |
| Total Liabilities | 215.5M | 174.1M | 190.7M | 237.2M | 166.0M |
| Equity | |||||
| Common Stock | 3.0K | 2.0K | 2.0K | 1.0K | 24.0K |
| Retained Earnings | -1.4B | -1.4B | -1.3B | -1.1B | -575.4M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 308.2M | 245.2M | 228.0M | 253.7M | 388.1M |
| Key Metrics | |||||
| Total Debt | 113.2M | 116.2M | 119.3M | 77.1M | 14.4M |
| Working Capital | 159.4M | 143.2M | 123.5M | 68.3M | 382.3M |
Balance Sheet Composition
Genedx Holdings Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -21.0M | -52.3M | -175.8M | -549.0M | -245.4M |
| Depreciation & Amortization | 25.2M | 22.0M | 33.7M | 59.3M | 21.8M |
| Stock-Based Compensation | 32.2M | 9.1M | -326.0K | 42.0M | 219.4M |
| Working Capital Changes | -27.7M | -4.3M | 8.7M | -20.0M | -3.6M |
| Operating Cash Flow | 21.0M | -21.6M | -141.9M | -514.1M | -6.1M |
| Investing Activities | |||||
| Capital Expenditures | -19.0M | -5.5M | -5.2M | -7.2M | -9.4M |
| Acquisitions | -32.9M | - | -12.1M | -127.0M | 0 |
| Investment Purchases | -55.7M | -66.3M | -47.7M | 0 | - |
| Investment Sales | 46.0M | 41.7M | 17.8M | 0 | - |
| Investing Cash Flow | -61.5M | -30.1M | -55.4M | -134.2M | -9.4M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 0 | 0 | 48.5M | 0 | 0 |
| Debt Repayment | -3.7M | -3.2M | -5.6M | -3.3M | -13.5M |
| Financing Cash Flow | 43.0M | 43.3M | 186.0M | 392.0M | 492.5M |
| Free Cash Flow | 14.3M | -34.0M | -185.9M | -333.5M | -211.2M |
| Net Change in Cash | 2.6M | -8.4M | -11.4M | -256.3M | 476.9M |
Cash Flow Trend
Genedx Holdings Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
724.64
Forward P/E
33.95
Price to Book
6.63
Price to Sales
4.78
PEG Ratio
33.95
Profitability Ratios
Profit Margin
-4.92%
Operating Margin
-10.60%
Return on Equity
-7.60%
Return on Assets
-1.55%
Financial Health
Current Ratio
2.46
Debt to Equity
36.72
Beta
2.19
Per Share Data
EPS (TTM)
$-0.73
Book Value per Share
$10.54
Revenue per Share
$14.93
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| WGS | 1.9B | 724.64 | 6.63 | -7.60% | -4.92% | 36.72 |
| Thermo Fisher | 174.6B | 25.84 | 3.31 | 13.52% | 15.15% | 82.91 |
| Danaher | 126.4B | 34.61 | 2.40 | 7.08% | 14.89% | 37.17 |
| CareDx | 1.1B | 13.98 | 3.37 | -6.27% | -5.62% | 8.64 |
| NeoGenomics | 1.0B | -9.42 | 1.22 | -12.43% | -14.85% | 48.95 |
| Opko Health | 936.6M | -4.08 | 0.73 | -17.14% | -37.19% | 31.29 |
Financial data is updated regularly. All figures are in the company's reporting currency.






